Tech Company Financing Transactions
Tolera Therapeutics Funding Round
Tolera Therapeutics secured a $5.4 million Series B financing round on 10/8/2012. Backers included Hopen Life Science Ventures, SWMF Life Science Venture Fund and Triathlon Medical Ventures.
Transaction Overview
Company Name
Announced On
10/8/2012
Transaction Type
Venture Equity
Amount
$5,406,298
Round
Series B
Investors
Hopen Life Science Ventures (Lead Investor) (Mark Olesnavage)
Proceeds Purpose
Tolera is planning to submit a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial comparing TOL101 to Thymoglobulin, the current market leading induction agent, for prevention of acute organ rejection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
P.O. Box 970
Portage, MI 49081
USA
Portage, MI 49081
USA
Phone
Website
Email Address
Overview
Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune suppression / modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Suzette Dutch
Chief Executive Officer
Ashleigh Palmer
Browse more venture capital transactions:
Prev: 10/8/2012: Pearl.com venture capital transaction
Next: 10/8/2012: Xeround venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs